

# Ocular Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/OF3DC1DB6A27EN.html>

Date: April 2022

Pages: 112

Price: US\$ 2,000.00 (Single User License)

ID: OF3DC1DB6A27EN

## Abstracts

Ocular Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Drugs In Development, 2022, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.

Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 13, 18, 1 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ocular Hypertension

(Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Ocular Hypertension - Overview

Ocular Hypertension - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Ocular Hypertension - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ocular Hypertension - Companies Involved in Therapeutics Development

Ocular Hypertension - Drug Profiles

Ocular Hypertension - Dormant Projects

Ocular Hypertension - Discontinued Products

Ocular Hypertension - Product Development Milestones

Featured News & Press Releases

Apr 11, 2022: Nicox's NCX 470 Dolomites phase 2 results published in Journal of Glaucoma

Feb 21, 2022: Nicox granted new patent for NCX 470 in China, extending coverage to 2039

Feb 11, 2022: Ocular therapeutix announces upcoming presentation of OTX-TIC Phase 1 Clinical Trial at Glaucoma

Dec 16, 2021: Nicox announces first patient in China screened in the ongoing NCX 470 Denali phase 3 trial in glaucoma

Nov 25, 2021: Notice of application for domestic manufacturing and marketing approval for K-232 treatment for glaucoma and ocular hypertension (ripasudil hydrochloride hydrate and brimonidine tartrate fixed combination eye drop)

Nov 10, 2021: Nicox's NCX 470 Dolomites phase 2 results in glaucoma patients to be presented at the AAO 2021 Annual Meeting

Oct 13, 2021: Aerie reports positive Phase III data for netarsudil ophthalmic solution

Sep 29, 2021: Nicox's NCX 470 shows retinal cell protection in a nonclinical model

Sep 02, 2021: Zhaoke Ophthalmology: Pivotal phase 3 clinical trial of Levobetaxolol hydrochloride eye drops met its primary endpoint

Jun 23, 2021: Nicox's NCX 470 dolomites phase 2 results in glaucoma patients to be presented at the World Glaucoma E-Congress 2021

Jun 21, 2021: Aerie Pharmaceuticals to present update on Rhopressa at the Raymond James Human Health Innovation Conference

May 14, 2021: SPARC announces positive top-line results from pivotal phase 3 clinical trial of PDP-716 for the treatment of open angle glaucoma or ocular hypertension

Mar 16, 2021: MediPrint Ophthalmics announces successful completion of its SIGHT-1 phase 2a clinical study

Jan 20, 2021: Ocular Therapeutix presents interim topline data from the phase 1 clinical trial of OTX-TIC in patients with primary open angle glaucoma or ocular hypertension at the 10th Annual Glaucoma 360 New Horizons Forum

Dec 11, 2020: Aerpio announces statistically significant topline results from Razuprotafib glaucoma phase 2 trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Ocular Hypertension, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Companies, 2022 (Contd..1)  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Companies, 2022 (Contd..2)  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Ocular Hypertension - Pipeline by Aadi Bioscience Inc, 2022  
Ocular Hypertension - Pipeline by AbbVie Inc, 2022  
Ocular Hypertension - Pipeline by Aerie Pharmaceuticals Inc, 2022  
Ocular Hypertension - Pipeline by Angelini Spa, 2022  
Ocular Hypertension - Pipeline by Betaliq Inc, 2022  
Ocular Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022  
Ocular Hypertension - Pipeline by D. Western Therapeutics Institute Inc, 2022  
Ocular Hypertension - Pipeline by Future Medicine Co Ltd, 2022  
Ocular Hypertension - Pipeline by Glaukos Corp, 2022  
Ocular Hypertension - Pipeline by Graybug Vision Inc, 2022  
Ocular Hypertension - Pipeline by Ikarovec Ltd, 2022  
Ocular Hypertension - Pipeline by Jenivision Inc, 2022  
Ocular Hypertension - Pipeline by Kowa Co Ltd, 2022  
Ocular Hypertension - Pipeline by Laboratoires Thea SA, 2022  
Ocular Hypertension - Pipeline by Laboratorios Sophia SA de CV, 2022  
Ocular Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, 2022  
Ocular Hypertension - Pipeline by MediPrint Ophthalmics Inc, 2022  
Ocular Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, 2022  
Ocular Hypertension - Pipeline by NicOx SA, 2022  
Ocular Hypertension - Pipeline by Noveome Biotherapeutics Inc, 2022  
Ocular Hypertension - Pipeline by Ocular Therapeutix Inc, 2022  
Ocular Hypertension - Pipeline by pH Pharma Co Ltd, 2022  
Ocular Hypertension - Pipeline by Qlaris Bio Inc, 2022

Ocular Hypertension - Pipeline by Santen Pharmaceutical Co Ltd, 2022  
Ocular Hypertension - Pipeline by Senju Pharmaceutical Co Ltd, 2022  
Ocular Hypertension - Pipeline by Shenzhen Hornetcorn Bio-technology Company Ltd, 2022  
Ocular Hypertension - Pipeline by Skye Bioscience Inc, 2022  
Ocular Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd, 2022  
Ocular Hypertension - Pipeline by Sun Pharmaceutical Industries Ltd, 2022  
Ocular Hypertension - Pipeline by Sustained Nano Systems LLC, 2022  
Ocular Hypertension - Pipeline by Sylentis SAU, 2022  
Ocular Hypertension - Pipeline by TaeJoon Pharmaceuticals Co Ltd, 2022  
Ocular Hypertension - Pipeline by ViSci Ltd, 2022  
Ocular Hypertension - Pipeline by Visus Therapeutics Inc, 2022  
Ocular Hypertension - Pipeline by Whitecap Biosciences LLC, 2022  
Ocular Hypertension - Dormant Projects, 2022  
Ocular Hypertension - Dormant Projects, 2022 (Contd..1)  
Ocular Hypertension - Discontinued Products, 2022



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Ocular Hypertension, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

## I would like to order

Product name: Ocular Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/OF3DC1DB6A27EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OF3DC1DB6A27EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

